Repligen reported $555.6M in Loan Capital for its fiscal quarter ending in September of 2026.





Loan Capital Change Date
Agilent USD 3.64B 594M Jun/2026
Align Technology USD 0 0 Dec/2024
Bio Techne USD 200M 0 Jun/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Bruker USD 1.7B 111.7M Sep/2026
Charles River Laboratories USD 2.44B 176.52M Sep/2026
Danaher USD 24.39B 759M Sep/2026
Dentsply International USD 1.98B 11M Sep/2026
General Electric Aerospace USD 16.99B 166M Sep/2026
Henry Schein USD 2.38B 82M Sep/2026
Illumina USD 1.79B 298M Sep/2026
IQVIA Holdings USD 14.82B 1.12B Sep/2026
Mettler Toledo International USD 1.96B 81.23M Sep/2026
Myriad Genetics USD 120.7M 400K Jun/2026
OraSure Technologies USD 100K 17K Dec/2025
Pacific Biosciences Of California USD 645.38M 223K Dec/2025
Pfizer USD 60B 498M Sep/2026
Repligen USD 555.6M 4.55M Sep/2026
Revvity USD 2.63B 968K Sep/2026
Standard Biotools USD 299K 0 Jun/2026
Thermo Fisher Scientific USD 39.11B 73M Sep/2026
Waters USD 5.09B 129M Jun/2026
West Pharmaceutical Services USD 202.9M 0 Sep/2026